H ypertrophic cardiomyopathy (HCM) is the most common genetic myocardial disease, transmitted as an autosomal dominant disease and generally caused by mutations in sarcomere protein genes. To date, >1400 individual mutations have been identified in 8 genes including MYH7 (cardiac β-myosin heavy chain), MYBPC3 (cardiac myosin-binding protein C), TNNT2 (cardiac troponin T), TNNI3 (cardiac troponin I), TPM1 (alpha tropomyosin), ACTC1 (cardiac actin), MYL2 (myosin light chain regulatory), and MYL3 (myosin light chain essential). 1 Thus, most HCM mutational screening programs are based on conventional sequencing of these genes, an approach which has provided a yield ranging from 30% to 60% of definitely or potentially pathogenic variants in consecutive HCM probands. 2, 3 In a considerable subset of patients, the molecular basis of the disease remains unresolved after conventional testing, particularly when the phenotype and clinical presentation are atypical, for example, in patients with apical HCM. 4, 5 associated with rare forms of HCM. 6 These include genes coding for proteins involved in intracellular calcium handling or constituting the Z-disc, the interface between the sarcomere and the cytoskeleton. 7, 8 However, such genes are rarely tested by conventional techniques because of time and cost restraints. In such perspective, the novel possibilities offered by nextgeneration sequencing (NGS) seem particularly advantageous in genetically heterogeneous conditions such as HCM, in that they allow the rapid and affordable analysis truly exhaustive of the spectrum of disease-associated genes reported in the literature. 9, 10 In the present study, the potential of NGS was used to investigate a large Italian family with atypical HCM and early onset of atrial fibrillation (AF), leading to the identification of a novel disease-causing variant in α-actinin 2 (ACTN2).
Methods

Clinical Evaluation
We assessed a large 4-generation Italian HCM family living in central and northern Italy. Direct clinical assessment and genetic testing were performed in 18 subjects including the proband (Figure 1 ). The study was approved by the hospital ethics committee, and all subjects gave informed consent. Available family members were assessed by clinical examination, ECG, echocardiography, and 24-hour Holter monitoring, performed blinded to (and often before) genetic testing. Two subjects (III-7, III-18), of which only 1 had a definite history of HCM, died before genetic testing could be performed; in both, autopsy reports were available. A detailed family history identified 3 additional family members with a history of cardiomyopathy and early arrhythmias, and 8 with nonspecific history of cardiac disease; all these subjects had died or were not available for further testing and, therefore, could not be included in the present analysis.
Comprehensive 2-dimensional and Doppler echocardiographic studies were performed using commercially available instruments, according to current guidelines. 11 The diagnosis of HCM was based on 2-dimensional echocardiographic evidence of a hypertrophied left ventricle (LV; maximal wall thickness ≥15 mm) in the absence of any other cardiac or systemic cause of hypertrophy. Regional LV noncompaction was defined by the presence of an end-systolic ratio of noncompacted to compacted myocardial layers >2. 12 Premature atrial contractions were defined as narrow QRS complexes, preceded by P waves with different morphology from the normal sinus P wave, occurring early after a normal sinus beat. Only a considerable arrhythmic burden (>2000 premature contractions on 24-hour Holter monitoring) or the presence of AF or flutter (>1 minute) were considered indicative of phenotypic expression of disease.
Genetic Studies
After genetic counseling and informed consent, genomic DNA was extracted from peripheral blood by standard protocols (QIAcube; Qiagen). Proband's DNA was screened by targeted massively parallel sequencing of 48 cardiomyopathy-associated genes, which were selected based on Human Gene Mutation Database Professional (Release 2009.4) 13 and OMIM Gene Database ( Table 1 ). The region of interest included the coding sequences of the genes (exons), and additional 25 bp of flanking sequences were added upstream and downstream each exon. The regions encompassing 221 829 bp were submitted to eArray tool (Agilent Technologies, Santa Clara, CA). After a visual review to optimize the enrichment, the panel was manufactured by Agilent (Agilent Technologies). In-solution hybridization capture was performed using the SureSelect kit (Agilent Technologies), and enriched fragment libraries were sequenced by 2×150 bp paired-end sequencing protocol on the Illumina MiSeq (San Diego, CA). All the reads were aligned against the human reference genome Hg19 with BWA version 0.7.7. 14 SAMtools version 0.1.19 15 was used to process the alignment result. Single nucleotide variants and insertion/deletions were detected by the Genome Analysis Toolkit (version 2.5.2) 16 and functionally annotated by ANNOVAR. 17 The issue of crosscapture of homologous regions in the MYH6 and MYH7 genes was dealt with by paired-end sequencing, local realignment of reads, and Sanger confirmation, as suggested in current guidelines. 18 To identify clinically relevant variants, data were filtered based on minor allele frequency using dbSNP Release 137, Exome Sequencing Project, and 1000 Genomes Project. Human Gene Mutation Database Professional was used to identify previously reported variants. 19 Subsequently, the variant list was filtered according to the location (coding, 5′ or 3′ junctions), the effect on protein, the evolutionary conservation of the affected nucleotide (PhyloP score), and pathogenic potential by in silico predictive algorithms such as MutationTaster, 20 sorts intolerant from tolerant, 21 and polymorphism phenotyping v2 22 .
Conventional Sanger sequencing was used to confirm the presence of selected variants in the proband to analyzed healthy controls and to perform family study. 23 
Results
Clinical Characterization
The present study assessed clinical and genetic features of 18 subjects from a large 4-generation Italian family. In 1 additional patient, who died before genetic testing was available, retrospective clinical evidence was collected. Of these, 11 individuals had evidence of cardiomyopathic involvement, transmitted with an autosomal dominant inheritance pattern, comprising variable combinations of 3 distinctive features: asymmetrical LV hypertrophy (LVH) consistent with HCM, early onset of supraventricular arrhythmias and atrioventricular (AV) block, and regional LV noncompaction ( Table 2) . The proband (II-15) was an 82-year-old man with mild, asymmetrical LV hypertrophy localized to the basal and midseptum, marked biatrial dilatation, and a restrictive LV filling pattern with preserved systolic function. He had been diagnosed with nonobstructive HCM almost 3 decades earlier and followed at our institution since 2005. Remarkably, he had a history of paroxysmal AF that presented at the age of 30, which subsequently evolved into permanent AF with advanced AV block, requiring VVI pacing at the age of 68 ( Figure 2 ). In 2008, he proved to be negative for mutations in the coding regions and splice sites of the 8 most prevalent sarcomere genes. Despite his early onset of disease manifestations and adverse cardiac remodeling, consistent with restrictive evolution of HCM, he remained fully active with only mild functional limitation (functional class New York Heart Association class II). Furthermore, he remained free from cardioembolic complications although he repeatedly refused treatment with oral anticoagulants. He currently remains on diltiazem, loop diuretics, kanrenone, and lowdose aspirin. His pacemaker had been replaced 4× and has never been upgraded to an implantable defibrillator; no significant ventricular arrhythmias have been noted on repeated 24-hour ECG Holter monitoring. His pro-brain natriuretic peptide in 2009 was 1013 pg/mL. Three additional family members had similar echocardiographic and clinical features, characterized by nonobstructive HCM with restrictive evolution, AV block, and biatrial dilatation: the proband's brother (II-5), aged 80 years, who developed permanent AF at the age of 64 and required VVI pacing for advanced AV block at 68 years, and 2 of his nephews (III-6 and III-7). Patient III-6 was a 50-year-old man with a long-standing history of frequent ventricular ectopic beats and sustained supraventricular arrhythmias associated with apical HCM and regional LV noncompaction; he recently developed paroxysmal AF and advanced AV block requiring permanent pacing. His brother (III-7) required surgery at the age of 15 because of a large atrial septal defect (ostium secundum) associated with unusually poor hemodynamic tolerance and severe right-sided heart failure, likely because of the diffuse myopathic substrate. At that age, he already showed first-degree AV block and frequent supraventricular ectopic beats; his echocardiogram showed apical HCM with marked biatrial dilatation (Figure 3) . He unfortunately died of heart failure-related complications a few years later. The 4-year-old son of patient III-6 (IV-2) presented at birth with esophageal atresia and tracheal fistula associated with ostrium secundum atrial septal defect, requiring surgery. He had multiple runs of supraventricular tachycardia, but no evidence of LVH or noncompaction. Intraoperative surgical biopsy of the ventricular septum showed cardiomyocyte hypertrophy and the typical features of HCM, which cannot be explained on the basis of the atrial septal defect (Figure 4) . The remaining patients all showed milder forms of cardiac disease, including mild apical LVH (patient III-26), regional LV noncompaction (patients III-13 and IV-8, associated with first-degree AV block in the former), left atrial dilatation and very frequent premature atrial contractions (>2000/24-hour Holter ECG) or AF (patients III-17, III-21, and III-24, associated with first-degree AV block in the latter), and left atrial dilatation with first-degree AV block (patient III-19). None of the genotype-negative family members had evidence of heart disease suggesting genetic transmission of the cardiomyopathic trait; specifically, none had >200 premature atrial contractions per 24 hours (Figure 1 ). When a comparison was performed by using the cut-off of >2000 premature atrial contractions per 24 hours, only 3 of 100 consecutive HCM patients from our cohort (aged 40±12 years) exceeded this threshold (3%; each >55 years of age), compared with 5 of 18 in our family (28%; P=0.002). Individual II-7 had a history of hypertension, dyslipidemia, and developed ischemic heart disease requiring coronary artery bypass grafting at the age of 69. The echocardiography performed showed a cardiopathy characterized by concentric LVH, left atrial dilatation, and akinesia of the septum segments, with a reduced ejection fraction. He also developed permanent AF and complete AV block requiring pacing. However, the late onset of symptoms and the evidence of severe coronary artery disease both suggested a nongenetic cause of the cardiac disease. Subject III-18 died suddenly at the age of 49: autopsy showed evidence of ischemic heart disease associated with coronary atherosclerosis, with no evidence of LVH, disarray, or interstitial fibrosis.
NGS Study Results
A total of 1 310 060 reads were obtained by targeted sequencing and 1 308 546 (>99%) reads were mapped on human genome by BWA. About 64% of the reads mapped on targeted regions. A mean coverage of 497× was obtained, and >99.9% of the targeted regions were covered >20×. Data analysis identified 438 variants, 126 of which are located in coding regions and intron-exon junctions. By excluding variants with minor allele frequency >5% in 1000 Genomes Project, 6 variants were obtained. Of these, 4 variants [TTN (NM_003319) c.21977G>A (p.Arg7326Gln); TTN (NM_003319) c.874 9A>C (p.Thr2917Pro); ACTN2 (NM_001103) c.683T>C (p.Met228Thr) and OBSCN (NM_001098623) c.13475T>G (p.Leu4492Arg)] were ultimately selected because (1) very low minor allele frequency, (2) affecting a highly evolutionary conserved residue, and (3) predicted as potentially pathogenic by in silico tools (Table 3) . 24, 25 
Cosegregation Analysis
Cosegregation analysis by conventional Sanger sequencing was performed in 18 family members, including 11 affected and 7 healthy individuals to assess cosegregation of the 4 variants identified. The novel variant ACTN2 c.683T>C (p.Met228Thr), located in the actin-binding domain ( Figure 5 ), proved to be the only mutation fully cosegregating with the cardiomyopathic trait in the family, in that it was found in all patients and was absent in 570 alleles of healthy individuals (Table 2) . Conversely, cosegregaton analysis excluded a pathogenic role for TTN c.21977G>A (p.Arg7326Gln; absent in affected individuals III-17, III-26, III-13, III-21, III-24, III,19, III-6, IV-8, IV-2), TTN c.8749A>C (p.Thr2917Pro; absent in affected individuals III-26, III-24, III-6, IV-8, IV-2), and OBSCN c.13475T>G (p.Leu4492Arg; absent in affected individuals III-17, III-26, III-13, III-21, III-24, III,19, III-6, IV-8, IV-2). 
Discussion
The present study shows the potential of NGS techniques applied to the identification of rare causal variants in patients with genetic heart disease, such as HCM, and a negative first-line approach by conventional Sanger sequencing. 26, 27 In a large, clinically heterogeneous Italian family spanning 4 generations, NGS analysis identified the novel heterozygous missense sequence variant ACTN2 c.683T>C (p.Met228Thr), which convincingly cosegregated with a complex cardiomyopathic trait, characterized by the interplay of midapical, nonobstructive HCM, early onset of AF and AV block, as well as regional LV noncompaction. These results support the role of Z-disc protein as a rare cause of HCM with atypical manifestations. 28
ACTN2 and Z-Disc Protein Genes as a Cause of HCM
Our family displayed several atypical features compared with classic HCM. First, patients with HCM presented with mild to moderate midapical LVH, with slow but distinctive progression toward a restrictive pathophysiology; none of our patients had LVH preferentially localized to the basal septum or anterior wall, as in classic HCM, and none had dynamic LV outflow obstruction. These features are consistent with ACTN2-related HCM recently described in an Australian family. 29 Ostium secundum atrial septal defect was present in 2 brothers and one of their sons: the latter finding was confined to a single branch of the family, suggesting fortuitous association of distinct genetic defect superimposed to ACTN2-related disease. However, screening for candidate genes associated with this phenotype was not performed in our study. 30 Furthermore, our family exhibited a spectrum of clinical manifestations beyond LVH, including supraventricular arrhythmias, AV blocks, and regional LV noncompaction, which were associated with HCM in the most affected family members including the proband, but were present in isolation (ie, in the absence of LVH) in subjects with milder disease. Notably, in most patients, frequent premature atrial contraction, often developing into AF or flutter, represented the initial clinical manifestation. In 2 of 3 mutation carriers with echocardiographically normal LV, the only associated abnormality was a mild to moderate dilatation of the left atrium. These arrhythmic manifestations were deemed to be an essential part of the phenotypic spectrum, for the following reasons: (1) this family has been followed at our institution for >2 decades; during this time, the onset of supraventricular arrhythmias has followed a common pattern, initially presenting with very frequent premature atrial contractions, proceeding to paroxysmal AF (at ages between 30 and 50) and then to permanent AF, requiring a pacemaker because of slow ventricular conduction; (2) this pattern has been consistently observed both in patients with and without LV hypertrophy; (3) supraventricular arrhythmias are rare in young individuals, in the absence of hypertension, coronary disease, or heart failure (as was the case in our patients); indeed, no or only very rare (<100 per 24 hours) premature beats were observed in genotype-negative family members. Indeed, the presence of these arrhythmic manifestations in this family has been so consistent as to allow clinical prediction with regard to the presence of the mutation in the absence of other signs of disease. These findings suggest that ACTN2 mutations may directly participate in the genesis of familial supraventricular arrhythmias.
Conversely, we found little propensity to malignant ventricular arrhythmias in our patients, in that none of the affected individuals died suddenly or had sustained VT or cardiac arrest, even when marked progression of disease was noted. The most striking example is represented by the proband, who remains active and with only mild functional limitation at 90 years of age. The only patient who died prematurely had undergone repair of an extensive atrial septal defect during adolescence, and his demise largely resulted from right heart failure secondary to the hemodynamic consequences of the congenital defect on a cardiomyopathic substrate. The relatively favorable long-term clinical course in our family is in contrast with that of the ACTN2 pedigree described by Chiu et al, 29 characterized by elevated prevalence of progressive heart failure and sudden cardiac death. Such discrepancy is evident despite the fact that both ACTN2 mutations occur within the actin-binding domain, in 2 adjacent calponin homology domains, suggesting that different mutations in this gene may dictate radically diverse clinical evolution and arrhythmic profile. This is in line with the heterogeneity of phenotypes associated with ACTN2, which include HCM with sigmoidal-type hypertrophy and even dilated cardiomyopathy. 29 In a larger perspective, such diversity highlights the broad pathophysiological implications of mutations affecting the molecular apparatus connecting the cardiomyocyte contractile apparatus to the cytoskeleton and muscle membrane, involving other HCM-associated genes such as titin, telethonin, muscle LIM, and myozenin.
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Emerging Role of NGS in HCM
Despite the remarkable wealth of information provided during the past 2 decades by Sanger-based techniques, 1-5,31-33 a strong urge remains to expand the possibilities of genetic testing in patients with HCM, because of clinical implications such as establishing a correct diagnosis, identifying family members at risk, and, in the foreseeable future, customizing treatment. 1 The advent of NGS has raised considerable expectations by virtue of its huge diagnostic potential and rapidly decreasing costs. 34, 35 In clinical practice, targeted NGS analysis allows rapid testing for a large number of genes that have been associated with HCM in the literature, such as ACTN2, but are necessarily excluded from Sanger sequencing packages because of the low yield and limited cost efficacy. Several groups have been applying targeted NGS to HCM and have emphasized its excellent sensitivity. [36] [37] [38] [39] Therefore, it is foreseeable that NGS will soon become the reference technique in this disease, a silent revolution characterized by both undeniable benefits and complexities. 35 A direct comparison of genotyping accuracy between Sanger and NGS is beyond the aims of this study, focusing on a single family. Nevertheless, even a systematic assessment of all known HCM-associated genes is not expected to dramatically increase the yield of genetic testing. 37 For example, in the first 140 patients analyzed at our institution on 48 genes, a pathogenic or likely pathogenic mutation was found in 68% of consecutive probands, that is, a limited increase compared with our 64% yield with Sanger-based techniques (unpublished observation). This is likely because of our incomplete knowledge of the molecular basis of HCM; however, it is debatable whether much higher rates will ever be achieved at all. Specifically, it is too early to know whether a more comprehensive approach, such as exome sequencing, will change the present status. 40 Conversely, it is now clear that the increase in background noise, that is, the yield of variants with uncertain clinical significance, is very large and poses considerable challenges. 37 As for all revolutions in genetic testing, the interpretation of NGS results requires clinical validation by familial cosegregation studies supporting a causal role for novel variants. Indirect evidence, such as in silico analysis or residue conservation among species, may be of help but cannot be considered definitive per se, and functional analyses are not always feasible or practical. Thus, painstaking clinical work assembling large pedigrees with powerful statistical potential remains a key element of success. 18, 24, 25, 41 Else, the background noise associated with variants of unknown significance, a constant finding in HCM cohorts screened by conventional techniques, will exponentially increase with NGS. In the present study, a case in point is represented by the novel variants found in TTN, which might have been considered pathogenic in our proband before cosegregation analysis. 42
Conclusions
A targeted NGS approach allowed the identification of a novel ACTN2 variant associated with midapical HCM, LV noncompaction, and juvenile onset of AF, emphasizing the potential of this technique in HCM diagnostic screening. Our findings support the concept that disruption of the Z-disc may be associated with considerable phenotypic and clinical heterogeneity, including structural and arrhythmic manifestations.
